tiprankstipranks
Advertisement
Advertisement
TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged
PremiumRatingsTG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged
1M ago
TG Therapeutics announces Briumvi data, initiates clinical trial
Premium
The Fly
TG Therapeutics announces Briumvi data, initiates clinical trial
1M ago
Corinne Johnson Reiterates Hold Rating on Briumvi Developer, Keeps Price Target Unchanged at $41 Amid Long-Term Potential and Execution Risks
Premium
Ratings
Corinne Johnson Reiterates Hold Rating on Briumvi Developer, Keeps Price Target Unchanged at $41 Amid Long-Term Potential and Execution Risks
1M ago
TG Therapeutics reports positive Phase 3 ENHANCE trial results
PremiumCompany AnnouncementsTG Therapeutics reports positive Phase 3 ENHANCE trial results
1M ago
Morning Movers: Dycom skyrockets after first quarter results
Premium
The Fly
Morning Movers: Dycom skyrockets after first quarter results
1M ago
TG Therapeutics reports ENHANCE trial meets primary endpoint
Premium
The Fly
TG Therapeutics reports ENHANCE trial meets primary endpoint
1M ago
TG Therapeutics completes enrollment in Briumvi trial
PremiumThe FlyTG Therapeutics completes enrollment in Briumvi trial
3M ago
TG Therapeutics Files Procedural 8-K on Financial Obligation
Premium
Company Announcements
TG Therapeutics Files Procedural 8-K on Financial Obligation
4M ago
TG Therapeutics secures additional $500M in non-dilutive capital
Premium
The Fly
TG Therapeutics secures additional $500M in non-dilutive capital
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100